Mcrae Capital Management Inc. boosted its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 120,729 shares of the biopharmaceutical company’s stock after buying an additional 50 shares during the period. Celgene Corporation makes up approximately 6.2% of Mcrae Capital Management Inc.’s holdings, making the stock its largest position. Mcrae Capital Management Inc.’s holdings in Celgene Corporation were worth $15,022,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CELG. Diversified Trust Co raised its position in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares in the last quarter. South Texas Money Management Ltd. increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 15 shares during the last quarter. Cadence Bank NA increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock worth $933,000 after buying an additional 45 shares during the last quarter. Washington Trust Bank increased its stake in shares of Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 46 shares during the last quarter. Finally, Beach Investment Management LLC. increased its stake in shares of Celgene Corporation by 0.8% in the first quarter. Beach Investment Management LLC. now owns 6,200 shares of the biopharmaceutical company’s stock worth $771,000 after buying an additional 50 shares during the last quarter. 78.34% of the stock is currently owned by institutional investors and hedge funds.

Celgene Corporation (NASDAQ:CELG) traded down 0.28% during midday trading on Friday, reaching $129.68. The company’s stock had a trading volume of 2,313,034 shares. The stock has a market capitalization of $101.46 billion, a PE ratio of 40.16 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The firm’s 50-day moving average price is $133.39 and its 200-day moving average price is $125.39.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter last year, the business posted $1.44 EPS. On average, analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Celgene Corporation (CELG) Shares Bought by Mcrae Capital Management Inc.” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/26/celgene-corporation-celg-shares-bought-by-mcrae-capital-management-inc.html.

A number of brokerages have recently commented on CELG. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a research note on Tuesday. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research note on Wednesday, August 16th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $175.00 target price on shares of Celgene Corporation in a research note on Wednesday, August 9th. Cann restated a “buy” rating and issued a $175.00 target price on shares of Celgene Corporation in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC restated a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $147.44.

In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the sale, the insider now directly owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders have sold a total of 253,761 shares of company stock valued at $33,792,445 in the last three months. Company insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.